reports
- Geir Hiller Holom
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK4.00) - Transition on track
While the Q4 report contained no big surprises, Nykode Therapeutics said its transition into a “leaner, research- and technology-driven organisation” is on track. CFO Harald Gurvin said he believes it could reach the targeted cost base of cUSD20m per annum as soon as 2026. Following the strategic pivot, the company is focusing on: 1) asset generation; and 2) value creation through seeking early-stage partnerships. We reiterate our BUY and NOK4 target price.
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- Sean Conroy
Nykode Therapeutics - Repositioned to streamline clinical progress
Nykode Therapeutics is a clinical-stage biopharmaceutical company with a focus on novel immunotherapies. As part of its Q324 results, it announced a strategic repositioning as a leaner organisation, aiming to streamline its clinical development efforts. With US$124.6m in cash and a runway guided into 2030, Nykode is seeking partnerships for cancer vaccine candidates VB10.16 and VB10.NEO. Both are backed by encouraging early clinical data and have potentially large commercial opportunities, but t...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK4.00) - Q3 report; major cost cuts un...
As we expected, Nykode Therapeutics today announced large cost cuts as well as other cost-containment initiatives to further extend its financial runway following the termination of the collaboration with Genentech. It also announced initiation of the C-05 trial and part two of the C-03 trial will be contingent on securing a partnership.
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK4.00) - Set for Q3e after major setba...
We believe the company will implement larger cuts in the organisation as well as other cost-preservation initiatives to further extend the financial runway following the termination of the collaboration with Genentech. Despite the extra uncertainty around the technology’s clinical potential following the termination (causing us to completely remove the NEO programme from our model until we see the clinical effect data from the N-02 trial), we believe the current valuation (well below Q2 cash) is...
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona. The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK21.00) - It’s all about the partners
Following the decision to discontinue the C-04 trial, we expect limited value from data within the guided runway. We continue to like the technology’s outlook and believe partnerships could create material shareholder value short- to mid-term. We reiterate our BUY, but have cut our target price to NOK21 (31).
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Q2 report and C-04 discontin...
The company announced it has decided to discontinue the C-04 trial based on standard-of-care changes and feedback from key opinion leaders. Regarding the recently announced Genentech reorganisation, it said that it has “not received any indications of the partnership being affected”.
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces Issuance of Key Patent Covering Individu...
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”. The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in develop...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco. Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data...
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Sup...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format. This latest study demonstrated that the APC-targeted va...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.